2.47
+0.125(+5.34%)
Currency In USD
Address
1601 Trapelo Road
Waltham, MA 02451
United States of America
Phone
781 819 0080
Website
Sector
Healthcare
Industry
Biotechnology
Employees
99
First IPO Date
August 06, 2021
| Name | Title | Pay | Year Born |
| Julie Green | Chief Human Resources Officer | 542,353 | 1975 |
| Timothy Lee | Chief Commercial Officer | 553,865 | 1974 |
| William E. Duke Jr. | Chief Financial Officer, Principal Accounting Officer & Principal Executive Officer | 635,543 | 1972 |
| Robert D. Allen | Chief Scientific Officer | 828,180 | 1969 |
| Jill Andersen | Chief Legal Officer & Corporate Secretary | 931,680 | 1973 |
| Mark A. Wingertzahn | Senior Vice President of Clinical Development & Medical Affairs | 0 | 1971 |
| Scott Young | Senior Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Katie Falzone | Senior Vice President of Finance | 0 | N/A |
| Kristie Coneys Kuhl | Chief Communications Officer | 0 | N/A |
| Rachael Gerlach | Senior Vice President of Regulatory Affairs | 0 | N/A |
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.